Maraviroc (Selzentry, Celsentri)

Published September 24, 2007; Updated October 19, 2011
Susa Coffey, MD
http://hivinsite.ucsf.edu/InSite?page=ar-06-01
Selected Reference
11. Saag M, Ive P, Heera J, et al. A multicenter, randomized, double-blind, comparative trial of a novel CCR5 antagonist, maraviroc versus efavirenz, both in combination with Combivir (zidovudine [ZDV]/lamivudine [3TC]), for the treatment of antiretroviral naive patients infected with R5 HIV 1: Week 48 results of the MERIT study. In: Program and abstracts of the 4th IAS Conference on HIV Pathogenesis, Treatment and Prevention; July 23-25, 2007; Sydney, Australia. Abstract WESS104.